<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndrome</z:e> is a very <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It is estimated that there are 1-2 cases out of 1 million inhabitants in the USA and 1/360,000 in France </plain></SENT>
<SENT sid="2" pm="."><plain>However, many patients are diagnosed very late or not at <z:hpo ids='HP_0000001'>all</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore the real prevalence is likely to be higher </plain></SENT>
<SENT sid="4" pm="."><plain>CAPS encompasses the three entities <z:e sem="disease" ids="C1610600" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">familial cold autoinflammatory syndrome</z:e> (FCAS), the <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> and the <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>)/<z:hpo ids='HP_0011010'>chronic</z:hpo> infantile neurologic cutaneous and articular (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>) syndrome </plain></SENT>
<SENT sid="5" pm="."><plain>They have in common a causative mutation in the NLRP3-gene </plain></SENT>
<SENT sid="6" pm="."><plain>The altered gene product cryopyrin leads to activation of the inflammasome which in turn is responsible for excessive production of IL-1β </plain></SENT>
<SENT sid="7" pm="."><plain>IL-1β causes the inflammatory manifestations in CAPS </plain></SENT>
<SENT sid="8" pm="."><plain>These appear as systemic <z:mp ids='MP_0001845'>inflammation</z:mp> including <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:hpo ids='HP_0002315'>headache</z:hpo> or <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e>, progressive <z:mp ids='MP_0004740'>sensorineural hearing loss</z:mp>, musculoskeletal manifestations and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> symptoms (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e> only) </plain></SENT>
<SENT sid="9" pm="."><plain>With the advent of the IL-1 inhibitors anakinra, rilonacept and canakinumab for the first time safe and effective therapeutic options are available for this devastating disease </plain></SENT>
<SENT sid="10" pm="."><plain>To prevent severe and possible life-threatening disease sequelae, early and correct diagnosis and immediate initiation of therapy are mandatory </plain></SENT>
</text></document>